CN108653218B - 作为alk/fak/igf1r多激酶抑制剂的吡咯并嘧啶衍生物的药物制剂组合物及其制备方法 - Google Patents
作为alk/fak/igf1r多激酶抑制剂的吡咯并嘧啶衍生物的药物制剂组合物及其制备方法 Download PDFInfo
- Publication number
- CN108653218B CN108653218B CN201710211956.XA CN201710211956A CN108653218B CN 108653218 B CN108653218 B CN 108653218B CN 201710211956 A CN201710211956 A CN 201710211956A CN 108653218 B CN108653218 B CN 108653218B
- Authority
- CN
- China
- Prior art keywords
- formula
- compound
- weight percent
- minutes
- magnesium stearate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
原辅料名称 | 用量(%,w/w) |
式(I)化合物 | 10 |
二氧化硅 | 5 |
微晶纤维素PH102 | 75 |
交联羧甲基纤维素钠 | 3 |
十二烷基硫酸钠 | 6 |
硬脂酸镁 | 1 |
包衣粉 | 3 |
原辅料名称 | 用量(%,w/w) |
式(I)化合物 | 28.5 |
二氧化硅 | 5 |
微晶纤维素PH102 | 60.5 |
交联羧甲基纤维素钠 | 5 |
硬脂酸镁 | 1 |
包衣粉 | 3 |
原辅料名称 | 用量(%,w/w) |
式(I)化合物 | 75 |
预胶化淀粉 | 10 |
微晶纤维素PH102 | 10 |
交联羧甲基纤维素钠 | 5 |
药动学参数 | 实施例1 | 实施例2 | 实施例4 |
AUC<sub>0-48h</sub>(hr*ng/mL) | 3638 | 1640 | 6813 |
T<sub>1/2</sub>(hr) | 14.4 | 27.0 | 12.7 |
Cmax(ng/mL) | 229 | 129 | 379 |
Tmax(hr) | 2.54 | 3.04 | 3.00 |
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710211956.XA CN108653218B (zh) | 2017-04-01 | 2017-04-01 | 作为alk/fak/igf1r多激酶抑制剂的吡咯并嘧啶衍生物的药物制剂组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710211956.XA CN108653218B (zh) | 2017-04-01 | 2017-04-01 | 作为alk/fak/igf1r多激酶抑制剂的吡咯并嘧啶衍生物的药物制剂组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108653218A CN108653218A (zh) | 2018-10-16 |
CN108653218B true CN108653218B (zh) | 2022-02-01 |
Family
ID=63784227
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710211956.XA Active CN108653218B (zh) | 2017-04-01 | 2017-04-01 | 作为alk/fak/igf1r多激酶抑制剂的吡咯并嘧啶衍生物的药物制剂组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108653218B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113087709A (zh) * | 2020-01-09 | 2021-07-09 | 沈阳药科大学 | 吡咯并嘧啶类衍生物及其制备方法和应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103476776A (zh) * | 2011-01-07 | 2013-12-25 | 北京赛林泰医药技术有限公司 | 作为FAK/Pyk2抑制剂的2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物 |
-
2017
- 2017-04-01 CN CN201710211956.XA patent/CN108653218B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103476776A (zh) * | 2011-01-07 | 2013-12-25 | 北京赛林泰医药技术有限公司 | 作为FAK/Pyk2抑制剂的2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物 |
Also Published As
Publication number | Publication date |
---|---|
CN108653218A (zh) | 2018-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI682789B (zh) | 控釋藥物組合物及其製備方法 | |
CA2933403C (en) | Pharmaceutical compositions comprising azd9291 | |
RU2404775C2 (ru) | Фармацевтические композиции, содержащие иматиниб и замедлитель высвобождения | |
TWI649098B (zh) | (s)-(1-((4-(3-(5-氯-2-氟-3-(甲基磺醯胺基)苯基-1-異丙基-1h-吡唑-4-基)嘧啶-2-基)胺基)丙-2-基)胺基甲酸甲酯之固體醫藥調配物 | |
NZ555901A (en) | Matrix type sustained-release preparation containing donepezil hydrochloride and / or memantine hydrochloride | |
CN101720221A (zh) | 用于制备含他达那非的药物的方法 | |
CN101278932A (zh) | 含有扎托布洛芬的缓释药物组合物及其制备方法与应用 | |
KR20190049543A (ko) | 붕해가 개선된 경구용 고형 제제 조성물 및 이의 제조 방법 | |
CN104523695A (zh) | 一种治疗过度增生性疾病的药物组合物 | |
WO2015032873A1 (en) | High-load pharmaceutical compositions comprising abiraterone acetate | |
EP3616696A1 (en) | Orally administrable enzalutamide-containing pharmaceutical composition | |
EP1976522B1 (en) | Pharmaceutical composition containing montelukast | |
CN107303278B (zh) | 一种hc-1119固体分散体及其制备方法 | |
AU2020209940A1 (en) | Solid micronized melatonin composition | |
CN112603900A (zh) | 含[(4-羟基-1-甲基-7-苯氧基-异喹啉-3-羰基)-氨基]-乙酸的固体制剂 | |
CN108653218B (zh) | 作为alk/fak/igf1r多激酶抑制剂的吡咯并嘧啶衍生物的药物制剂组合物及其制备方法 | |
EP3620156A1 (en) | Composition having improved water solubility and bioavailability | |
WO2014063596A1 (zh) | 一种治疗糖尿病的口服制剂 | |
WO2020122244A1 (ja) | 錠剤及びその製造方法 | |
US9775832B2 (en) | Pharmaceutical composition for oral administration | |
WO2019030691A1 (en) | EXTRUDED COMPOSITIONS OF ENZALUTAMIDE | |
JP6847190B2 (ja) | 矯味剤含有顆粒を内在する、服用性が改善された口腔内崩壊錠 | |
JP6423035B2 (ja) | イミダフェナシン含有造粒物のコーティング顆粒 | |
WO2017093890A1 (en) | Clobazam tablet formulation and process for its preparation | |
WO2019132840A1 (en) | A pharmaceutical formulation for oral administration comprising dabigatran etexilate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20190516 Address after: 100176 Beijing Economic and Technological Development Zone, No. 99 Kechuang 14th Street, 33 Building D, 2213 on the second floor (centralized office area) Applicant after: Capital Pharmaceutical Holdings (Beijing) Co., Ltd. Address before: 100195 No. 15 Building, Yuquan Huigu, No. 3 Minzhuang Road, Haidian District, Beijing Applicant before: Beijing Centaurus Biopharma Technology Co., Ltd. |
|
TA01 | Transfer of patent application right | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Address after: 100176 No. 2213, 2nd floor, building D, building 33, 99 Kechuang 14th Street, Beijing Economic and Technological Development Zone, Beijing (centralized office area) Applicant after: Capital Pharmaceutical Holdings (Beijing) Co.,Ltd. Address before: 100176 No. 2213, 2nd floor, building D, building 33, 99 Kechuang 14th Street, Beijing Economic and Technological Development Zone, Beijing (centralized office area) Applicant before: Shouyao holding (Beijing) Co.,Ltd. |
|
CB02 | Change of applicant information | ||
GR01 | Patent grant | ||
GR01 | Patent grant |